Teleflex Incorporated Stock

$129.42

3.86% today

NYSE, Aug 22, 10:00 pm CET

ISIN

US8793691069

Symbol

TFX

Reports

Quarter | Annual

Index

NYSE Composite

Sector

Health Care Equipment & Services

Industry

Health Care Equipment & Supplies

Overview Dividends Analysts Charts News Strategies

Teleflex Incorporated Stock price

$124.61

-247.02 66.47% 5Y

NYSE, Closing price Thu, Aug 21 2025

-1.04 0.83%

ISIN

US8793691069

Symbol

TFX

Reports

Quarter | Annual

Index

NYSE Composite

Sector

Health Care Equipment & Services

Industry

Health Care Equipment & Supplies

Key metrics

Basic

Market capitalization

$5.5b

Enterprise Value

$7.2b

Net debt

$1.6b

Cash

$253.7m

Shares outstanding

44.2m

Valuation (TTM | estimate)

P/E

28.8 | 9.2

P/S

1.8 | 1.7

EV/Sales

2.4 | 2.3

EV/FCF

18.0

P/B

1.3

Dividends

DPS

$1.36

Yield 1Y | 5Y

1.1% | 0.5%

Growth 1Y | 5Y

0.0% | 0.0%

Payout 1Y | 3Y

91.3% | 24.5%

Increased

0 Years

Financials (TTM | estimate)

Revenue

$3.0b | $3.2b

EBITDA

$866.3m | $901.2m

EBIT

$592.8m | $799.2m

Net Income

$191.9m | $598.4m

Free Cash Flow

$396.4m

Growth (TTM | estimate)

Revenue

1.1% | 3.5%

EBITDA

6.0% | 9.9%

EBIT

5.6% | 46.4%

Net Income

-27.2% | 758.8%

Free Cash Flow

-5.0%

Financial Health

Equity Ratio

60.3%

Return on Equity

1.6%

ROCE

8.9%

ROIC

6.8%

Debt/Equity

0.4

EPS

$4.3

FCF per Share

$9.0

Short interest

3.2%

Employees

14k

Rev per Employee

$220.0k

As a Free StocksGuide user, you can view scores for all 7,015 stocks worldwide.

Get Started for Free Today

Teleflex Incorporated Stock Analysis

Unlock Scores for Free

??

21 Analysts have issued a Teleflex Incorporated forecast:

14x Hold

67%

6x Sell

29%

More details on Analyst Estimates Including Price Targets

21 Analysts have issued a Teleflex Incorporated forecast:

Buy

Hold

67%

Sell

29%

Analyst Estimates with Stock Price Targets

Financial data from Teleflex Incorporated

Income Statement P&L | Balance Sheet | Cash Flow

Quarter TTM Annually

Jun '25		+/- %
Revenue	3,041 3,041	1% 1% 100%
- Direct Costs	1,351 1,351	2% 2% 44%
Gross Profit	1,691 1,691	1% 1% 56%
- Selling and Administrative Expenses	940 940	3% 3% 31%
- Research and Development Expense	158 158	4% 4% 5%
EBITDA	866 866	6% 6% 28%
- Depreciation and Amortization	273 273	7% 7% 9%
EBIT (Operating Income) EBIT	593 593	6% 6% 19%
Net Profit	192 192	27% 27% 6%

In millions USD.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Subscribe Now

Teleflex Incorporated Stock News

Neutral

GlobeNewsWire

●

3 days ago

Teleflex Announces the Launch of Barrigel™ Rectal Spacer in Japan as a Proven Safe and Effective Option to Minimize the Harmful Long-Term Side Effects of Prostate Radiation Therapy

Innovative hyaluronic acid technology delivers enhanced control and precision, significantly lowering the risk of rectal toxicity during prostate radiation treatment. 1 - 4 Initial cases have now been performed in Japan.

Neutral

Seeking Alpha

●

22 days ago

Teleflex Incorporated (TFX) Q2 2025 Earnings Conference Call Transcript

Teleflex Incorporated (NYSE:TFX ) Q2 2025 Earnings Call July 31, 2025 8:00 AM ET Company Participants John R. Deren - Executive VP & CFO Lawrence Soren Keusch - Vice President of Investor Relations & Strategy Development Liam J.

Neutral

GlobeNewsWire

●

22 days ago

Teleflex Announces Quarterly Dividend

WAYNE, Pa., July 31, 2025 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE: TFX) announced today that its Board of Directors declared a quarterly cash dividend of thirty-four cents ($0.34) per share of common stock. The dividend is payable September 15, 2025, to shareholders of record at the close of business on August 15, 2025.

More Teleflex Incorporated News

Company Profile

Teleflex, Inc. provides medical technology products which enables healthcare providers to improve patient outcomes and enhance patient and provider safety. The company designs, develops, manufactures and supplies single-use medical devices used by hospitals and healthcare providers for common diagnostic and therapeutic procedures in critical care and surgical applications. It operates through the following business segments: Americas, EMEA (Europe, the Middle East and Africa), Asia (Asia Pacific) and OEM. The Americas segment engages in the sales of interventional urology products. The EMEA engages in the sales of urology products. The Asia segment designs, manufactures and distributes medical devices primarily used in critical care, surgical applications and cardiac care and generally serves hospitals and healthcare providers. The OEM segment designs, manufactures and supplies devices and instruments for other medical device manufacturers. Teleflex was founded in 1943 and is headquartered in Wayne, PA.

Head office	United States
CEO	Liam Kelly
Employees	14,100
Founded	1943
Website	www.teleflex.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

Start now